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Abstract
Background: Bone morphogenetic proteins (BMPs) are pleiotropic members of the TGF-beta
superfamily which regulate many biological processes during development and adult tissue
homeostasis and are implicated in the pathogenesis of a number of human diseases. Their
involvement in both normal and aberrant physiology creates a need for rapid, sensitive and
methodologically simple assays to evaluate their activity from a variety of biological samples.
Previously alkaline phosphatase based assays, ELISA and luciferase based bioassays have been
developed to evaluate either individual or total BMP activity. In this paper, we describe a highly
sensitive, rapid and specific cell based assay for the simultaneous quantification of total and isoform
specific BMP activity from biological samples.
Results: A C2C12 cell line stably transfected with a reporter plasmid consisting of the BMP
response element (BRE) from the Id1 promoter fused to a luciferase reporter gene was generated.
Exposure of this cell line to human recombinant BMP2, BMP4, BMP6, BMP7, BMP9 and BMP10
induced the expression of luciferase which was quantified using a luminometer. This assay was
specific for BMP activity as the other TGF-β superfamily members TGF-β 1, Nodal and Mullerian
Inhibiting Substance (MIS) did not induce the reporter. Pretreatment of samples with isoform
specific BMP blocking antibodies coupled with isoform specific titration analysis allowed the
simultaneous identification and quantification of BMP4, BMP6 and BMP9 in serum samples.
Conclusion: The assay is rapid (<48 hours) and can be used to simultaneously measure isoform
specific and total BMP activity in complex solutions.
Background
Bone morphogenetic proteins (BMPs) are members of the
TGF-β superfamily and were originally identified by their
ability to induce endochondral bone formation [1]. There
are at least 20 BMP family members and they are involved
in a myriad of biological processes both during embry-
onic development and adult life. These include pluripo-
tency of embryonic stem cells [2], dorsoventral patterning
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formation, osteoblastic differentiation and bone homeos-
tasis [3-5].
BMPs are synthesized as precursor proteins that are intra-
cellularly proteolytically cleaved following dimerization
to produce active mature protein dimers. The BMPs signal
via hetero-oligomeric complexes of combinations of three
type II receptors:- BMP receptor type II (BMPR2), activin
A receptor type IIa (ACVR2A/ACTRII) and ACVR2B
(ACTRIIB) and four type I receptors:- ACVRL1 (Activin
like kinase 1, ALK1), ACVR1 (ALK2), BMPR1A (ALK3)
and BMPR1B (ALK6) [6-9]. Following ligand induced
receptor hetero-oligomerization the type I receptors are
activated by type II receptor mediated phosphorylation
events. The receptor complexes then transduce their sig-
nals via activation of the canonical Smad pathway and
several non-Smad signalling pathways. The receptor regu-
lated Smads (R-Smads), Smad1, Smad5 and Smad8 are
directly phosphorylated by the type I receptor kinases
which enables complex formation with the co-Smad,
Smad4. R-Smad/Smad4 complexes accumulate in the
nucleus and regulate target gene expression by binding to
gene regulatory elements and recruiting transcriptional
co-repressor and/or activation complexes [10].
As well as playing critical roles in normal physiological
processes, dysregulation of BMP signalling can have
pathophysiological consequences [11]. Mutations of BMP
receptors have been observed in several human patholo-
gies. For example, inactivation of ALK1 results in Heredi-
tary Hemorrhagic Telangiectasia type 2 (HHT2) [12] and
mutations of BMPR2 are found in primary pulmonary
arterial hypertension patients [13] and pancreatic cancers
[14]. Similarly, polymorphisms/mutations have also been
observed in BMPs in several human pathologies [11]. Evi-
dence is also accumulating to suggest that aberrant expres-
sion of the BMPs may also have pathological
consequences. Decreased expression of BMP7 in primary
breast cancer specimens has been associated with bone
metastasis [15] and is reduced in advanced prostate aden-
ocarcinoma [16]. In contrast elevated BMP7 levels corre-
late with shorter tumour recurrence in malignant
melanoma [17] and increased BMP7 levels in colorectal
cancer correlates with depth of tumour invasion, liver
metastasis, advanced Duke's classification and poor prog-
nosis [18]. Elevated levels of BMP7 have also been
observed in the synovial fluid from rheumatoid arthritis
patients [19]. BMP4 levels have also been found to
increase in late colonic adenocarcinomas and are higher
in primary colonic carcinomas with liver metastasis than
matched normal mucosa [20]. BMP6 levels have been
observed to decrease in diffuse large B cell lymphoma and
correlate with reduced survival [21] and to be elevated in
prostate cancer [22]. BMP2 expression has also been
observed to be elevated in lung tumours [23].
The observations that BMP signalling may play important
roles in both normal and aberrant physiology suggest that
the ability to conveniently measure BMP bioactivity in
biological samples may have clinical diagnostic and prog-
nostic value and this has driven the development of ELISA
[24,25], enzyme linked immunoreceptor assays (ELIRA)
[26] and cell based assays to measure BMP activity [27].
The inhibitor of differentiation transcription factor Id1 is
an immediate early BMP target gene and the BMP respon-
sive elements of the human and mouse Id1 promoters
have been well characterised [28]. Synthetic engineering
of two copies of the BMP response elements of the mouse
Id1 gene enabled the generation of a highly specific and
sensitive BMP responsive luciferase based reporter con-
struct termed BRE-Luc [28]. Recent reports have described
the development of BRE-Luc based bioassays in stable
reporter cell lines which are capable of measuring the
activity of BMP2, 4, 6 and 7 [29,30]. Here we describe the
development of a C2C12 BRE-Luc bioassay cell line. We
demonstrate that this cell line is capable of measuring the
activity of BMP2, BMP4, BMP6, BMP7, BMP9 and BMP10
at physiological concentrations and show that by using
isoform specific blocking antibodies this assay can be
used to measure simultaneously the levels of BMP4,
BMP6 and BMP9 in fetal calf serum (FCS) and human
serum samples. This assay paves the way for measuring
the activity of multiple BMPs in complex biological sam-
ples.
Results
Generation of a stable BMP reporter cell line
The BMP responsive C2C12 mouse myoblast cell line was
stably transfected with the BRE-Luc construct which con-
tains the BMP responsive elements of the mouse Id1 gene
cloned into the pGL3 luciferase vector [28]. Multiple sta-
ble clones were tested for BMP inducibility in media con-
taining 0.1% serum by treatment with 5 ng/ml
recombinant BMP9 (GDF2). Clone 22 (named
C2C12BRE) was found to be the most sensitive (data not
shown) and was used for all subsequent experiments. This
cell line was maintained in 0.7 mg/ml G418 for routine
passage and tested at each passage for BMP responsive-
ness. We found no change in the BMP responsiveness of
C2C12BRE cells measured over 20 passages and after mul-
tiple rounds of storage in liquid nitrogen and re-culture
(data not shown).
Dose dependent induction of luciferase by multiple BMPs 
in C2C12BRE cells
Having established that the C2C12BRE cells were sensi-
tive to BMP9 treatment we investigated the dose depend-
ent effects of multiple recombinant BMPs on this cell line.
Cells were incubated with increasing concentrations of
recombinant human BMP2, BMP4, BMP6, BMP7, BMP9
and BMP10. All 6 BMPs tested stimulated luciferase activ-
ity in a dose dependent manner, with maximal stimula-Page 2 of 11
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BMC Cell Biology 2009, 10:20 http://www.biomedcentral.com/1471-2121/10/20tion reached with >50 ng/ml (>2 nM) BMP2, 2 ng/ml (77
pM) BMP4, >50 ng/ml (>1.66 nM) BMP6, 10 ng/ml (427
pM) BMP7, 5 ng/ml (205 pM) BMP9 and 20 ng/ml (820
pM) BMP10 (Figure 1A–F and data not shown). We next
assessed the specificity of the assay for BMPs by treating
the cells with other members of the TGF-β superfamily.
TGF-β1, Nodal and Mullerian Inhibiting Substance (MIS)
failed to increase luciferase activity, even at concentrations
as high as 10 ng/ml (400 pM) TGF-β1, 200 ng/ml (7.75
nM) Nodal or 1640 ng/ml (70 nM) MIS (Figure 1G–I).
Having observed that BMPs stimulate luciferase produc-
tion in C2C12BRE cells over a range of concentrations in
an isoform specific fashion, we next determined the linear
range of the assay with each BMP tested. We found that
BMP-specific dose dependent induction of BRE-Luc activity in C2C12BRE cellsFigure 1
BMP-specific dose dependent induction of BRE-Luc activity in C2C12BRE cells. C2C12BRE cells were seeded over-
night in 24 well plates at 2 × 104 cells per well and serum starved in DMEM containing 0.1% FCS for 7 hours. After serum star-
vation, cells were incubated without or with increasing concentrations of recombinant human (A) BMP2, (B) BMP4, (C) BMP6, 
(D) BMP7, (E) BMP9, (F) BMP10, (G) TGF-β1, (H) Nodal and (I) MIS. After 16 hours of treatment, BRE-luciferase activity was 
assessed by measuring luciferase activity in cell lysates. Luciferase activities were normalised to protein content and fold induc-
tions relative to untreated samples were determined. Each point represents the mean ± SEM of three independent experi-
ments performed in quadruplicate.
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BMP4, 10 ng/ml (333 pM) BMP6, 10 ng/ml (427 pM)
BMP7, 1 ng/ml (40 pM) BMP9 and 5 ng/ml (205 pM)
BMP10 (Figure 2A–E and data not shown). Using these
titration analyses we also determined the lower sensitivity
limits for each BMP. We could reproducibly measure as
little as 0.05 ng/ml (2 pM) BMP4, 0.5 ng/ml (16.5 pM)
BMP6, 1 ng/ml (42 pM) BMP7, 0.1 ng/ml (4.1 pM) BMP9
and 1 ng/ml (41 pM) BMP10 (Figure 2 and data not
shown). Thus, this assay is sensitive and robust enough to
measure 0.05–1 ng/ml (2–40 pM) BMP4, 0.1–1 ng/ml
(4–40 pM) BMP9, 0.5–10 ng/ml (16.5–333 pM) BMP6,
1–10 ng/ml (42–427 pM) BMP7 and 1–5 ng/ml (40–205
pM) BMP10.
Simultaneous measurement of multiple BMPs from 
biological samples
The ability of the assay to measure many different BMPs
over physiological concentrations prompted us to investi-
gate if we could use the assay in combination with specific
blocking antibodies to measure the activity of different
BMPs in biological samples. As the assay could measure
BMP4, BMP6 and BMP9 over at least a tenfold range of
concentrations we focused our efforts on these isoforms.
First we determined the ability of commercially available
blocking antibodies to block induction of reporter activity
by recombinant BMPs. Cells were treated with an excess of
recombinant BMPs (5 ng/ml (192 pM) BMP4, 20 ng/ml
(666 pM) BMP6 and 5 ng/ml (205 pM) BMP9) with or
without a 20 minute pre-treatment with increasing con-
centrations of their matched blocking antibodies. The
minimum concentration required for complete inhibition
of BMP induced luciferase activity for each BMP was deter-
mined as 5 ng/ml BMP4 antibody (Figure 3A), 2 ng/ml
BMP6 antibody (Figure 3B) and 0.1 ng/ml BMP9 anti-
body (Figure 3C). We next assessed the specificity of these
blocking antibodies by treating C2C12BRE cells with sev-
eral BMPs (BMP2, BMP4, BMP6, BMP7, BMP9 and
BMP10) and the blocking antibodies for BMP4, BMP6
and BMP9 (Figures 3D–I). BMP4 induced luciferase activ-
Determination of the linear range of activation of BRE-Luc by BMPsFigu e 2
Determination of the linear range of activation of BRE-Luc by BMPs. C2C12BRE cells were treated as in Figure 1 
with increasing concentrations of (A) BMP4, (B) BMP6, (C) BMP7, (D) BMP9 and (E) BMP10. Luciferase activity was normalised 
to protein content. Relative luciferase units (RLU) following background subtraction are shown. Data shown is a representative 
experiment performed in quadruplicate ± SD.
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BMP6 induced luciferase activity was only blocked by
BMP6 antibody (Figure 3E) and BMP9 induced luciferase
activity was only blocked by BMP9 antibody (Figure 3F).
Likewise, the blocking antibodies only blocked their
respective BMP (Figure 3D–I).
We next determined that culture of our cells in 10% FCS
did not significantly affect cell proliferation or morphol-
ogy in our assay conditions (data not shown). This fact
coupled with the sensitivity of the assay and the availabil-
ity of the specific blocking antibodies allowed us to
develop a method for the quantification of a specific BMP
in FCS which we used as a test complex biological sample
(See Figure 4). C2C12BRE cells were treated with media
containing 10% FCS with and without pre-incubation of
the media with 0.1 ng/ml BMP9 blocking antibody. The
antibody treated samples produced less relative luciferase
units than the untreated samples indicating the presence
of BMP9 in this serum sample (Figure 4). C2C12BRE cells
were also treated with three different concentrations of
BMP9 over the pre-established linear range in parallel to
generate a standard curve. By measuring the change in
luciferase activity (Δ luciferase) and then extrapolating
this value to the BMP9 standard curve we determined that
this sample contained 6.14 ng/ml BMP9 (Figure 4).
Next we performed a similar analysis by treating cells with
three different concentrations within the linear range of
recombinant BMP4, BMP6 and BMP9 to generate stand-
ard curves (Figure 5A, B, C respectively) and in parallel
incubated samples with 10% FCS containing media with
and without blocking antibodies to BMP4, BMP6 and
BMP9. Treatment with each of the blocking antibodies
revealed that FCS contained all three BMPs (Figure 5D).
Measurement of Δ luciferase units and extrapolation to
the standard curves indicated that BMP4, BMP6 and
BMP9 were present in FCS at concentrations ranging from
2.75–6.14 ng/ml (Figure 5E).
Having determined that FCS contains BMPs 4, 6 and 9 we
tested if the concentrations of these BMPs varied over dif-
ferent batches of FBS obtained from different sources. We
found that treatment of the three serum samples with the
BMP4, BMP6 and BMP9 blocking antibodies reduced luci-
ferase measurements in all three cases (Figure 6A) indicat-
ing that these different batches of serum all contained
BMP4, BMP6 and BMP9. Addition of the Δ luciferase
obtained with each antibody also indicated that serum 1
and serum 2 samples contained an additional activity
capable of inducing the BRE-Luc construct indicating that
FCS is likely to contain at least one other BMP (labelled as
BMPX, Figure 6A). The total amount of luciferase activity
induced by serum stimulation varied approximately two
fold between serum samples (Figure 6A) as did the
amount of each of the BMPs 4, 6 and 9 (Figure 6B). BMP9
was found in a higher concentration than BMP4 and
BMP6 in all samples whereas the relative amounts of
BMP4 to BMP6 varied between samples (Figure 6B).
Having identified and quantified BMP4, 6 and 9 in FCS
we performed similar analysis on human serum samples.
We readily detected BMP4 in three out of four human
serum samples in concentrations ranging from 0.44–1.24
ng/ml (Figure 6C, D). Similarly we detected from 1.18 to
1.84 ng/ml BMP9 in all four human serum samples tested
(Figure 6C, D). We did not detect BMP6 or any other BMP
activity in human serum samples (Figure 6C). Taken
together these findings indicate that our assay is capable
of determining the relative amounts of BMP4, BMP6 and
BMP9 from complex biological solutions.
Discussion
The pleiotropic and fundamental roles of BMPs in both
normal physiological and pathophysiological processes,
indicates that the ability to measure BMP activity may
have clinical use. In this paper we describe the develop-
ment of a highly sensitive and specific assay to measure
BMP activity from biological samples. We generated a sta-
ble cell clone "C2C12BRE" expressing a luciferase reporter
under the control of the BMP response elements from the
mouse Id1 promoter. When compared to other available
bioassays, our assay has enhanced BMP isoform range,
increased sensitivity and is capable of simultaneously
measuring multiple individual BMP isoforms from the
same complex biological samples.
The most widely used cell based assay to assess BMP activ-
ity employs measurement of alkaline phosphatase activity
in C2C12 myoblast cells [27]. However, this assay may
lack sufficient sensitivity to measure physiological levels
of BMPs, takes several days to perform and is susceptible
to influence from other signalling pathways [31,32].
Recently, other cell based assays using C3HT10T1/2
embryonic mouse cells [30], C2C12 and HepG2 cells [29]
have been described. These assays are capable of measur-
ing BMP2, BMP4, BMP6 and BMP7. We show that our
assay is also capable of measuring BMP9 levels from 4–
200 pM and BMP10 levels from 40–205 pM. Our assay
has enhanced sensitivity for BMP4 (2 pM compared to 3
pM), BMP6 (16.5 pM compared to 40 pM) and BMP7 (42
pM compared to 125 pM). ELISA assays are commercially
available for the measurement of BMP4, BMP6 and BMP7
but are currently unavailable for BMP9 and BMP10. BMP4
ELISAs are reported to measure 0.03–2 ng/ml (RnD Sys-
tems, USA) and 0.015–1 ng/ml (Raybiotech, USA) similar
to the sensitivity of our assay (0.05–1 ng/ml). An ELISA
for BMP6 is reported to measure 0.08–8 ng/ml (Raybio-
tech, USA) similar to our assay sensitivity range (0.5–10
ng/ml). A BMP7 ELISA is reported to have enhanced sen-Page 5 of 11
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Inhibition of BMP mediated activation of BRE-Luc with specific blocking antibodiesFigure 3
Inhibition of BMP mediated activation of BRE-Luc with specific blocking antibodies. C2C12BRE cells were treated 
as in Figure 1 with (A) 5 ng/ml BMP4, (B) 20 ng/ml BMP6 and (C) 5 ng/ml BMP9 with or without increasing concentrations of 
BMP4, BMP6 and BMP9 specific blocking antibodies respectively (D, E, F, G, H, I). C2C12BRE cells were treated as in Figure 1 
with 5 ng/ml BMP4 (D), 20 ng/ml BMP6 (E), 2 ng/ml BMP9 (F), 50 ng/ml BMP2 (G), 10 ng/ml BMP7 (H) or 20 ng/ml BMP10 (I) in 
the presence or absence of 5 ng/ml BMP4 antibody, 2 ng/ml BMP6 antibody or 0.1 ng/ml BMP9 antibody. Luciferase activity was 
normalised to protein content and fold inductions relative to non-BMP treated samples are shown. Each point represents the 
mean ± SEM of three independent experiments performed in quadruplicate.
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BMC Cell Biology 2009, 10:20 http://www.biomedcentral.com/1471-2121/10/20sitivity but limited linearity (0.01–1 ng/ml, Raybiotech,
USA) when compared to our bioassay (1–10 ng/ml). Our
assay therefore has similar sensitivity to ELISA assays but
has the advantage that it measures biologically active BMP
and not total BMP levels. Importantly, we develop the
bioassay methodology further and show that by using
BMP isoform specific blocking antibodies it is possible to
measure the specific activity of individual BMPs in com-
plex biological samples whereas previous methods have
so far only been capable of detecting total BMP activity.
Furthermore using recombinant BMPs and isoform spe-
cific blocking antibodies we demonstrate that is possible
to simultaneously quantitate total BMP activity and indi-
vidual isoform BMP activity from the same biological
sample.
As shown in Figure 1 our assay is specific for BMPs as
related TGF-β superfamily members TGF-β, Nodal and
MIS had no effect on luciferase activity. By careful titration
analysis we were able to define the linear ranges of activity
for different BMP isoforms. Our assay is most sensitive for
measuring the activity of BMP4, BMP6 and BMP9 and is
capable of measuring as little as 40 pM of BMP7 and
BMP10 (Figure 2). As we could measure BMP4, BMP6 and
BMP9 over greater than 10 fold ranges of concentrations
coupled with the availability of isoform specific blocking
antibodies for these species we focused our efforts on
developing the assay using these BMPs. Using recom-
binant BMPs and blocking antibodies we demonstrated
that it is possible to determine the specific activity of indi-
vidual BMPs (Figure 3).
We next used FCS as a test complex biological fluid for
determining the versatility of our assay. By performing
titration analysis with recombinant BMP9 and serum
stimulation of C2C12BRE cells with and without BMP9
blocking antibody we discovered that FCS contains high
levels of biologically active BMP9 ranging from 5–10 ng/
ml (Figures 4, 5, 6). Whilst this paper was in preparation,
Sabine Bailly and colleagues discovered that BMP9 is
present in human serum at similar concentrations from
2–12 ng/ml and acts as a circulating vascular quiescence
factor [33]. Our data indicates that BMP9 may also play
roles during bovine development and reveals a remarka-
bly conserved steady state level of BMP9 in serum samples
between species. BMP9 has been shown to signal via ALK1
in endothelial cells [8] and indicates that either C2C12
cells express functional ALK1 or that BMP9 may also
engage alternative receptors. We are currently investigat-
ing these hypotheses. Our analysis also revealed that FCS
contains BMP4 ranging from 3–5 ng/ml and BMP6 rang-
ing from 2.75–8 ng/ml (Figure 6). BMP4 has previously
been purified from FCS [34] but our study is the first to
measure the concentration of BMP4 in FCS. To our knowl-
edge this current study is the first to identify BMP6 in FCS.
Methodology for the analysis of BMP9 content inserumFigure 4
Methodology for the analysis of BMP9 content inse-
rum. C2C12BRE cells were treated as indicated in Figure 1 
and were stimulated with 10% FCS in the absence or pres-
ence of 0.1 ng/ml BMP9 antibody. Luciferase activities were 
normalised to protein content and relative luciferase units 
(RLU) were calculated following subtraction of background 
values obtained from unstimulated cells. The mean decrease 
of RLU in the presence of BMP9 antibody was calculated (Δ 
luciferase units). In the same experiment C2C12BRE cells 
were treated with increasing concentrations of BMP9 within 
the linear range in order to calculate a standard curve for 
BMP9 activity as described in Figure 2. The equation of the 
line was solved and the relative amount of BMP9 calculated 
using the Δ luciferase value. To obtain total BMP9 concentra-
tion per ml of serum this value is multiplied by the dilution 
factor of 20. Data shown is a representative experiment per-
formed in quadruplicate ± SD.
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BMC Cell Biology 2009, 10:20 http://www.biomedcentral.com/1471-2121/10/20Our experiments also revealed that in two out of three FCS
samples the combined activity of BMP4, BMP6 and BMP9
could not account for the total BMP activity in these sam-
ples. We therefore conclude that FCS may also contain at
least one other BMP isoform (BMPX, Figure 6). Remarka-
bly, our studies reveal that FCS contains high levels of
BMP activity and that typical cell culture conditions of 5–
10% FCS contain BMP activity from 0.5–2 ng/ml of BMPs.
Given the profound biological effects of BMP signalling
on cell biology and the interaction of these events with
other signalling cascades, we believe that it is important to
consider the potential effects of BMP signalling when
assessing tissue culture experimental results.
As well as measuring BMPs in FCS we expanded our anal-
ysis and found that BMP9 is present in human serum in
1–2 ng/ml quantities in concordance with recently pub-
lished findings [33]. To the best of our knowledge we
identify BMP4 as a human serum factor for the first time.
We failed to detect BMP6 or any other BMP activity capa-
ble of inducing BRE-Luc in human serum indicating that
BMP4 and BMP9 maybe the only circulating BMPs
present in normal human serum.
An increasing body of evidence is revealing that aberrant
BMP signalling and changes in BMP levels may have
important biological consequences during normal and
pathophysiological processes [11]. We have demonstrated
Simultaneous analysis of multiple BMPs in a serumsampleFig re 5
Simultaneous analysis of multiple BMPs in a serumsample. C2C12BRE cells were treated as in Figure 4 with increasing 
concentrations of BMP4 (A), BMP6 (B) or BMP9 (C) within the linear range. Standard curves for (A) BMP4, (B) BMP6 and (C) 
BMP9 were calculated. (D) Other C2C12BRE cells were incubated with 10% FCS, from Autogen Bioclear, batch 212-181107, 
in the absence or presence of 5 ng/ml BMP4 antibody, 2 ng/ml BMP6 antibody or 0.1 ng/ml BMP9 antibody. After 16 hours of 
treatment, cells were lysed and luciferase activity and protein content were determined and the relative luciferase units were 
calculated as described in Figure 2. (E) Δ luciferase units for each BMP were calculated as described in Figure 4, and the BMP 
content was calculated by extrapolating the Δ luciferase units' value for each BMP in the appropriate standard curve.
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BMC Cell Biology 2009, 10:20 http://www.biomedcentral.com/1471-2121/10/20that our bioassay is capable of measuring the activity of
individual BMP isoforms from serum samples. It is an
exciting possibility that determination of BMP levels in
patient biological samples such as serum, or body cavity
fluids may have prognostic and/or diagnostic utility in the
management of human disease. Recent studies have also
suggested the possibility of using recombinant BMPs to
treat osteogenic disease [35]. The use of BMP bioassays
may also be useful in monitoring the bioactivity of BMPs
in these clinical settings. Our assay could also be used in
determining the specificity and efficacy of agents designed
to target BMP signalling. With the increasing availability
of commercial BMP blocking antibodies and recombinant
proteins it should be possible to broaden the applicability
of our bioassay. Furthermore, by extrapolating the meth-
odology we describe new cell lines capable of measuring
Analysis of  concentration of multiple BMPs in bovine and human serum samplesFigure 6
Analysis of  concentration of multiple BMPs in bovine and human serum samples. (A and C) C2C12-BRE cells were 
treated as described in Figure 4 with three separate batches of FCS (bovine serum 1–3) or four different batches of human 
serum (human serum 1–4) with and without 5 ng/ml BMP4 antibody, 2 ng/ml BMP6 antibody and 0.1 ng/ml BMP9 antibody in 
separate wells. After 16 hours of treatment, cells were lysed and luciferase activity and protein content were determined and 
the relative luciferase units were calculated as described in Figure 2. Δ luciferase units for each BMP was calculated as described 
in Figure 4 and are displayed as part of the total luciferase activity obtained when serum was added in absence of blocking anti-
bodies. Remaining luciferase activity induced by serum but not blocked by BMP4, BMP6 and BMP9 antibodies is labelled as 
BMPX. (B and D) By extrapolating the Δ luciferase units for each BMP in the appropriate standard curve, the amount of BMP4, 
BMP6 and BMP9 in each serum was calculated. Data shown is the mean ± SD of a representative experiment performed in 
quadruplicate.
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BMC Cell Biology 2009, 10:20 http://www.biomedcentral.com/1471-2121/10/20further isoforms of BMP for the use in laboratory research
and clinical practice could be developed.
Conclusion
We have generated a rapid, sensitive and specific bioassay
for the simultaneous measurement of total and individual
isoform BMP activity from complex biological solutions.
This assay can be used to study BMP activity in experimen-
tal and clinical settings and to screen for pharmacological
modifiers of BMP signalling.
Methods
Reagents
Recombinant human TGF-β was purchased from Pepro-
tech (Peprotech, UK). Recombinant human BMP2, BMP4,
BMP6, BMP7, BMP9, BMP10, MIS and Nodal were pur-
chased from R&D Systems Inc. Each growth factor was
resuspended in 1 mM HCl/1 mg/ml BSA and used at
appropriate concentrations. The following blocking anti-
bodies were purchased from R&D Systems and resus-
pended in PBS and used at the appropriate
concentrations: monoclonal anti human BMP9 antibody
(MAB3209), polyclonal anti human BMP6 antibody
(AF507) and monoclonal anti human BMP4 antibody
(MAB757). Different batches of FCS were tested for the
presence of BMPs. Batch 108005 from Autogen Bioclear
(bovine serum #1), batch 212-181107 from Autogen Bio-
clear (bovine serum #2) and batch CSE0442 from Perbio
(bovine serum #3). Different batches of human serum
were purchased from Sigma, 078K1708 (human serum
#1), 078K1707 (human serum #2), 078K1823 (human
serum #3) and 117k1692 (human serum #4).
Generation of reporter cell line
C2C12 mouse myoblast cell line was cultured in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 2 mM L-glutamine, 100 U/ml of penicillin, 100 U/ml
streptomycin and 10% fetal calf serum (FCS) and were
grown at 37°C in 10% CO2. To generate BMP reporter cell
line, C2C12 cells were stably transfected with pGL3(BRE)-
luciferase reporter construct [28]. 0.6 × 106 C2C12 cells
were plated in a 10 cm dish and were transfected the next
day with 8 μg pGL3(BRE)-luciferase reporter construct
and 1 μg G418 resistant plasmid pTK-neo [36] using
Hiperfect transfection reagent (Qiagen, Crawley, UK)
according to manufacturer's instructions. Three days later
the cells were plated at different densities and selected for
antibiotic resistance using 700 μg/ml G418. Individual
clones were isolated, expanded and tested for BMP induc-
ibility of luciferase expression. Clone 22 was selected and
grown in the presence of 700 μg/ml G418, named C2C12-
BRE and used for all subsequent experiments.
BMP bioassay
C2C12-BRE cells were plated at a concentration of 2 × 104
per well in 24 well plates containing DMEM plus 10% FCS
and allowed to attach for 18 hours. Cells were washed
with PBS and re-fed with 0.5 mls of DMEM 0.1% FCS for
7 hours. Recombinant growth factors were added to cells
at the appropriate concentrations for 15 hours and then
cells were washed with PBS and lysed using 100 μl of
reporter lysis buffer (Promega, Madison, USA). To meas-
ure luciferase activity, 40 μl of lysate was added to 40 μl
Luciferase Assay Reagent (Promega) and luminescence
was quantitated using a Veritas Microplate Luminometer.
The protein concentration of each lysate was analyzed
using Bio-Rad protein assay reagent according to the man-
ufacturer's instructions (Biorad, USA). Luciferase units
obtained were normalized to the protein content of each
well. All experiments were performed at least three times
with four independent wells per condition.
BMP bioassay for the analysis of serum samples
Standard curves for each BMP to be analyzed were gener-
ated as above with BMP concentrations spanning the lin-
ear range of each BMP in each experiment. 100 μl serum
samples were divided in half and were treated or
untreated for 20 minutes with specific BMP blocking anti-
bodies at the concentration determined to be required to
block maximal recombinant BMP activation. Samples
were then diluted to 500 μl in DMEM and incubated with
the C2C12-BRE cells exactly as described above. Luciferase
activity was measured and normalised to protein content
and background values obtained from cells grown in
DMEM 0.1% FCS alone were subtracted to generate rela-
tive luciferase units (RLU). RLU values obtained in the
presence of the blocking antibody were subtracted from
the RLU values obtained without blocking antibody to
generate a Δ luciferase unit value. This value was used to
calculate the amount of each BMP assayed in the serum
samples by extrapolation from the standard curves.
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